Trial Profile
Phase II Study of Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2012
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Everolimus (Primary)
- Indications Pancreatic cancer
- Focus Biomarker; Therapeutic Use
- 22 Jun 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 02 Apr 2010 Actual patient number (16) added as reported by ClinicalTrials.gov.
- 02 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.